Despite overwhelming evidence in favor of methadone as a standalone treatment for opioid use disorder (OUD), the medicine continues to face political and cultural barriers in getting to the people who need it most.

This is demonstrated in the years-long intransigence of the Allegheny County Jail, finally broken down by the Department of Justice in a settlement last month. And it can be seen in opposition to the federal Modernizing Opioid Treatment Access Act (MOTAA), a common sense proposal to allow more physicians to prescribe methadone, getting the lifesaving drug to more people struggling with OUD.

Disease and treatment

Opioid use disorder is a disease, and like any disease it responds to medication.

Advertise with us

Opioids are a class of drugs, from codeine and morphine to heroin and fentanyl, that activate certain receptors on cells largely in the central nervous system. The resulting suppression of that system leads to various effects, such as pain relief, drowsiness and “euphoria.”

While opioids act in the same way inside every body, each person’s reaction is different. Some people, for genetic and social reasons, quickly become dependent on even weak opioids — that is, their bodies stop making essential opioid-like endorphins naturally — leading to OUD, or addiction. It then takes stronger and stronger opioids to avoid the horror of withdrawal. It’s not a matter of willpower; it’s a matter of biology.

There are three FDA-approved medicines to treat OUD: methadone, buprenorphine (brand name Suboxone) and naltrexone (brand name Vivitrol). The first two are themselves opioids that, when used properly, safely stave off withdrawal by replacing some of the effects of illicit opioids. The third works against the effects of opioids and is generally less effective, in part because it can only be started after at least a week of opioid abstinence.

As for the narcotic OUD medications, buprenorphine can be prescribed by any doctor and filled at pharmacies, while methadone — for now — can only be distributed under strict supervision at Opioid Treatment Program (OTP) sites, which offer services including counseling and accountability measures. Because methadone is generally a daily medication, a person in treatment for OUD must get to the clinic every day.

The problem? In many places, especially more rural areas, OTP sites are rare and far apart. Many people with OUD, especially those who are poor, can’t get to a site every day.

Advertise with us

Liberating methadone

MOTAA is a bipartisan proposal, approved Tuesday by the U.S. Senate Health, Education, Labor and Pensions committee. It will allow board-certified addiction doctors to prescribe methadone, and pharmacies to distribute it, outside the context of OTPs.

Much of the disagreement around methadone is related to two more acronyms: MOUD and MAT. MOUD refers to “medication for opioid use disorder,” and assumes that in many cases medication alone can treat addiction. MAT refers to “medication-assisted treatment,” and implies that medications such as methadone should only be used as part of a broader treatment strategy, including regular counseling and accountability check-ins. MAT is the logic behind the 70s-era opioid treatment programs that lock down methadone (but not buprenorphine) to this day.

Medical evidence, however, demonstrates that while some people need full-spectrum MAT, MOUD alone successfully treats many others. Methadone alone, for instance, is associated with a 50% decrease in mortality for people with OUD. Effective treatment will often require personalized trial and error.

Expanding access to methadone does come with some risks. It is possible to abuse the medication, like many other take-home prescriptions, even to the point of death. There is also a street market for methadone.

Advertise with us

But many other prescriptions come with even more serious side-effects and risks of abuse — fear of methadone is based more in opioid use stigma than hard evidence. And Canada and the United Kingdom have had looser methadone rules than the U.S. for decades, and disasters predicted by some MOTAA opponents have not come to pass.

Some argue that MOTAA doesn’t go far enough, and that all physicians and clinicians should be able to prescribe it for OUD. That may be — but it’s prudent now to test the waters with a modest expansion.

Healing, not torture

As for the Allegheny County Jail, the facility’s leaders long resisted the evidence in favor of MOUD, leaving hundreds of inmates to go through the nightmare of withdrawal in their cells. It’s likely this resistance to treating people with OUD led to some of the deaths at the jail.

After ignoring experts for years, the county only relented when the Department of Justice brought a civil rights case against the jail. Last month, the county agreed in a settlement to provide all FDA-approved medications for OUD to inmates — including methadone and buprenorphine.

Advertise with us

With competent medical oversight — which may be wishful thinking in a facility that notoriously hired a cruel and disgraced physician, Dr. Wilson Bernales, to provide care to inmates — having all three medications should allow the jail to tailor personalized care to people with OUD, so it can become a place of healing and not of torture.

This will require better administrative oversight: The DOJ settlement is meaningless if no one enforces it. County executive-elect Sara Innamorato should establish a clear chain of accountability for ACJ, one that includes but does not depend on the fractious and grandstanding Jail Oversight Board. The new warden, and the public, need to know exactly to whom he or she reports. For too long, the jail has operated on an island.

Whether it’s expanding access to methadone for people with MOUD in or out of prison, the evidence is clear: the benefits far outweigh the risks.